eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | barrett esophagus |
| Symptom | C0279628|esophageal adenocarcinoma |
| Sentences | 34 |
| PubMedID- 21345220 | Lgr5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without barrett's esophagus. |
| PubMedID- 23617672 | It is often difficult to accurately delineate the borders and extent of early-stage esophageal adenocarcinoma in patients with barrett's esophagus using conventional white light endoscopy. |
| PubMedID- 21820152 | The progression of intestinal metaplasia to esophageal adenocarcinoma in patients with barrett's esophagus is partly driven by chromosomal alterations that activate oncogenes and inactivate tumor suppressor genes. |
| PubMedID- 21309910 | Dysplasia and esophageal adenocarcinoma may arise in patients with barrett's esophagus after fundoplication esophageal ph monitoring showing no acid in esophagus. |
| PubMedID- 23243384 | For upper gi tract pathology i-scan assisted in diagnosis or therapy of barrett's esophagus with dysplasia, esophageal adenocarcinoma, hsv esophagitis, gastric malt lymphoma, gastric antral intestinal metaplasia with dysplasia, duodenal follicular lymphoma, and a flat duodenal adenoma. |
| PubMedID- 19850156 | Risk of esophageal adenocarcinoma and mortality in patients with barrett's esophagus: a systematic review and meta-analysis. |
| PubMedID- 20397052 | Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 24867156 | Recent findings: rfa is well tolerated and efficacious in most but not all barrett's esophagus patients with dysplasia and esophageal adenocarcinoma (eac). |
| PubMedID- 22272378 | found a correlation between cox2 expression and tp53 wild-type status in esophageal adenocarcinoma with barrett's esophagus as a precursor lesion, but not in scc, providing evidence that the participation of p53 in the regulation of cox2 expression in cancer may be dependent on tumor histology. |
| PubMedID- 21593708 | Incidence of esophageal adenocarcinoma with barrett esophagus (be) imposes a decision about therapy management. |
| PubMedID- 26202380 | Overexpression of cd55 from barrett's esophagus is associated with esophageal adenocarcinoma risk. |
| PubMedID- 23338150 | Therefore, telomerase inhibitors may exhibit high potency in the treatment of esophageal adenocarcinoma arising from barrett's esophagus. |
| PubMedID- 22796132 | Background& aims: proton pump inhibitors and nonsteroidal anti-inflammatory drugs might prevent esophageal adenocarcinoma in patients with barrett's esophagus (be), but there are limited data from clinical trials to support this concept. |
| PubMedID- 26068095 | We explored next-generation sequencing to detect mutations with the analytical sensitivity required to predict concurrent high-grade dysplasia (hgd) and esophageal adenocarcinoma (eac) in patients with barrett's esophagus by testing nonneoplastic bim. |
| PubMedID- 25843080 | Acid-suppressive medications and risk of esophageal adenocarcinoma in patients with barrett's esophagus(gut 2014;63:1229-1237). |
| PubMedID- 22443641 | Previously, the risk of progression to esophageal adenocarcinoma in patients with barrett's esophagus was thought to be approximately 1%. |
| PubMedID- 20188100 | However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (eac) in patients with existing barrett's esophagus (be) is unclear. |
| PubMedID- 23714382 | Background & aims: recent population-based studies have shown a low risk of esophageal adenocarcinoma (eac) in patients with nondysplastic barrett's esophagus (ndbe). |
| PubMedID- 22241250 | Use of statin medications and risk of esophageal adenocarcinoma in persons with barrett's esophagus. |
| PubMedID- 21115135 | The incidence of esophageal adenocarcinoma among patients with nondysplastic barrett's esophagus has been overestimated. |
| PubMedID- 25502158 | The goal of this study was to determine whether the use of metformin modifies the risk of development of esophageal adenocarcinoma in patients with barrett esophagus. |
| PubMedID- 26208896 | Background & aims: statins have been reported to protect against esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be). |
| PubMedID- 24681073 | Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with barrett's esophagus. |
| PubMedID- 21375764 | In contrast with the esophageal adenocarcinoma arising from barrett's esophagus in western countries, the major phenotype in the asia-pacific region is esophageal squamous cell carcinoma (escc) . |
| PubMedID- 20946664 | There were n = 41 esophageal adenocarcinomas (eac) with associated barrett's esophagus (be), n = 19 eac without be and n = 10 esophageal squamous-cell carcinomas of the esophagus (which were intended to serve as positive control for mmp-1 expression), and n = 18 barrett's biopsies without intraepithelial neoplasia or invasive carcinoma which were derived from patients with gastroesophageal reflux disease (gerd). |
| PubMedID- 22626608 | Background & aims: radiofrequency ablation (rfa) reduces the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus (be) with high-grade dysplasia (hgd), but its effects in patients without dysplasia are debatable. |
| PubMedID- 25621687 | The incidence of esophageal adenocarcinoma arising from barrett esophagus (be) has been rapidly increasing in many western countries over the past few decades.1–3 it also leads to increasing the rate of hospitalization for esophageal adenocarcinoma and causes a serious problem.4 endoscopic surveillance of be, the currently accepted standard, aims to reduce morbidity and mortality by early detection and endoscopic therapy of dysplasia or cancer.5–8 current guidelines from gastroenterology societies recommend endoscopic surveillance of be using white light endoscopy (wle) with targeted biopsies of any endoscopically visible lesions and 4 random quadrant biopsies from every 2 cm of the be segment (seattle protocol).7,9 however, it has been pointed out that this protocol has several limitations, such as time required, low compliance, and increased risk of sampling error.10 therefore, establishment of a more effective surveillance program for detecting dysplastic lesions or those with high malignant potential in be patients is highly desirable. |
| PubMedID- 22302717 | There is a critical need to identify molecular markers that can reliably aid in stratifying esophageal adenocarcinoma (eac) risk in patients with barrett's esophagus. |
| PubMedID- 24651385 | Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with barrett's esophagus: a meta-analysis. |
| PubMedID- 24570883 | Advanced esophageal adenocarcinomas arising from barrett esophagus (be) are tumors with an increasing incidence and poor prognosis. |
| PubMedID- 21698030 | The majority of lower esophageal adenocarcinomas appear in patients with barrett's esophagus (be), a premalignant condition in which the normal squamous epithelium is replaced by metaplastic columnar epithelium. |
| PubMedID- 24795040 | Background: proton pump inhibitors (ppis) may reduce the risk of esophageal adenocarcinoma (eac) in patients with barrett's esophagus. |
| PubMedID- 26233550 | Serum 25-hydroxyvitamin d levels and the risk of dysplasia and esophageal adenocarcinoma in patients with barrett's esophagus. |
| PubMedID- 25071359 | Lifetime risk of esophageal adenocarcinoma in patients with barrett's esophagus. |
Page: 1